Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.

ABSTRACT:

Aim

To use existing hepatitis C virus (HCV) antiviral therapies as access to new treatments is limited.

Methods

A PubMed search for randomised control trials or meta-analysis related to response-guided therapy of HCV genotype 1 patients was undertaken using pegylated interferon and ribavirin (PR), boceprevir (B) and telaprevir (T) and lead-in where response-guided therapy at TW4(TW4), 8(TW8), 10(TW10), or 12(TW12) based on HCVRNA(+) or HCVRNA(-). Studies presented at major conferences were also used. Where necessary, a post-hoc analysis was performed. A response-guided management roadmap was created based on sustained virological response (SVR).

Results

Starting with PR, those with HCVRNA(-) at TW4 have > 86% SVR, while those are HCVRNA(+) have 34%-41.7% SVR. HCVRNA(-

SUBMITTER: Lim SG 

PROVIDER: S-EPMC4323477 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature